Why Akorn, Inc. (AKRX) Shares Rallied on Monday
After surging sharply on Friday, Akorn, Inc.
Posts Tagged ‘Akorn Inc (AKRX)’
Why Akorn, Inc. (AKRX) Shares Spiked Higher
Akorn, Inc. (NASDAQ:AKRX) shares have surged 18% on Friday after Bloomberg reported that its sources say Fresenius SE 'is weighing a bid' to buy Akorn.
Billionaire John Paulson Boosts Stakes in Endo Pharmaceuticals, Akorn; Plus Top Three New Positions
Famous for his bet against subprime mortgages at the height of the US housing bubble, John Paulson was just another hedge fund manager prior to that.
Five Big Winners in Today’s Trading Session Include Biotech with Promising Drug That Cures Ebola-like Virus
U.S equities inched lower in early trading this morning following twin deadly attacks on Brussels' Zaventem airport and a metro train in the Belgian capital.
Activist Tom Sandell’s Newest Targets
Sandell Asset Management is a hedge fund that was founded in 1998 by activist investor Tom Sandell, who is currently the fund’s manager.
Top New Picks of Healthcare Fund Blue Jay Capital: Endo International plc (ENDP), Alkermes Plc (ALKS), Akorn Inc. (AKRX)
Healthcare-focused fund Blue Jay Capital Management, managed by Paul Sinclair, has disclosed its equity portfolio for the reporting period of March 31 in a 13F filed with the ...
Akorn, Inc. (AKRX), United Therapeutics Corporation (UTHR) Among Consonance Capital’s Winning Bets in Healthcare
The $5.50 billion pharmaceutical company Akorn, Inc. (NASDAQ:AKRX) was one of the top gainers on Wednesday, closing the session with an almost 10% gain.
Hedge Fund Resource Center
